Vivos Therapeutics (VVOS) Net Equity Issued and Repurchased (2020 - 2026)

Vivos Therapeutics (VVOS) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $342000.0 in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $342000.0 in Q1 2026; TTM through Mar 2026 was $9.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.6 million, down 28.48% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $342000.0, down from $2.8 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for VVOS reached as high as $3.5 million in Q4 2024 and fell as low as $342000.0 in Q1 2026.
• Historically, Net Equity Issued and Repurchased has averaged $2.3 million across 3 years, with a median of $2.6 million in 2025.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 19.97% in 2025 and fell as far as 19.97% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at $3.5 million in 2024, then slipped by 19.97% to $2.8 million in 2025, then tumbled by 87.79% to $342000.0 in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $342000.0 in Q1 2026, $2.8 million in Q4 2025, and $2.4 million in Q3 2025.